A5087569309- Bacterial Infections and Vaccines
- Bacteriophages and microbial interactions
- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
- Immunotherapy and Immune Responses
- Probiotics and Fermented Foods
- HIV Research and Treatment
- Viral-associated cancers and disorders
- Immune Cell Function and Interaction
- vaccines and immunoinformatics approaches
- Clostridium difficile and Clostridium perfringens research
- Gut microbiota and health
- Streptococcal Infections and Treatments
- Escherichia coli research studies
- Nanoplatforms for cancer theranostics
- Cell Adhesion Molecules Research
- Cancer Research and Treatments
- Glycosylation and Glycoproteins Research
- Pneumonia and Respiratory Infections
University of Trento
2017-2023
F-star (United Kingdom)
2013-2015
University of Sussex
2009
Bacterial outer membrane vesicles (OMVs) represent an interesting vaccine platform for their built-in adjuvanticity and simplicity of production process. Moreover, OMVs can be decorated with foreign antigens using different synthetic biology approaches. However, the optimal OMV engineering strategy, which should guarantee compartmentalization most heterologous in quantities high enough to elicit protective immune responses, remains validated. In this work we exploited lipoprotein transport...
Bacterial outer membrane vesicles (OMVs) are naturally produced by all Gram-negative bacteria and, thanks to their plasticity and unique adjuvanticity, emerging as an attractive vaccine platform. To test the applicability of OMVs in cancer immunotherapy, we decorated them with either one or two protective epitopes present B16F10EGFRvIII cell line tested activity OMV immunization C57BL/6 mice challenged B16F10EGFRvIII.The 14 amino acid B epitope human epidermal growth factor receptor variant...
Abstract Because of their potent adjuvanticity, ease manipulation and simplicity production Gram‐negative Outer Membrane Vesicles OMVs have the potential to become a highly effective vaccine platform. However, some optimization is required, including reduction number endogenous proteins, increase loading capacity with respect heterologous antigens, enhancement productivity in terms vesicles per culture volume. In this work we describe use Synthetic Biology create Escherichia coli...
In situ vaccination (ISV) is a promising cancer immunotherapy strategy that consists of the intratumoral administration immunostimulatory molecules (adjuvants). The rationale tumor antigens are abundant at site, and therefore, to elicit an effective anti-tumor immune response, all needed adjuvant, which can turn immunosuppressive environment into immunologically active one. Bacterial outer membrane vesicles (OMVs) potent adjuvants since they contain several microbe-associated molecular...
FS102 is a HER2-specific Fcab (Fc fragment with antigen binding), which binds HER2 high affinity and recognizes an epitope that does not overlap those of trastuzumab or pertuzumab. In tumor cells express levels HER2, caused profound internalization degradation leading to cell apoptosis. The antitumor effect in patient-derived xenografts (PDXs) correlated strongly the amplification status tumors. Superior activity over combination pertuzumab was observed vitro vivo when gene copy number equal...
Human FAT1 is overexpressed on the surface of most colorectal cancers (CRCs) and in particular a 25 amino acid sequence (D8) present one 34 cadherin extracellular repeats carries epitope recognized by mAb198.3, monoclonal antibody which partially protects mice from challenge with human CRC cell lines xenograft mouse models. Here we data immune competent demonstrating potential D8-FAT1 as cancer vaccine. We first demonstrated that homolog (mD8-FAT1) also expressed CT26 B16F10 murine lines....
Activation of the host gene egr1 is essential for lytic replication Epstein–Barr virus (EBV). activated by Zta (BZLF1, ZEBRA). interacts directly with DNA through a series closely related Zta-response elements (ZREs). Here we dissect mechanism used to interact promoter and identify weak interaction ZRE that dependent on distal part ZRE. Furthermore, demonstrate ability enhanced at least tenfold methylation. The transactivate reporter construct driven can be As methylated in EBV genome...
A large body of data both in animals and humans demonstrates that the gut microbiome plays a fundamental role cancer immunity determining efficacy immunotherapy. In this work, we have investigated whether to what extent can influence antitumor activity neo-epitope-based vaccines BALB/c-CT26 mouse model. Similarly observed C57BL/6-B16 model, Bifidobacterium administration per se has beneficial effect on CT26 tumor inhibition. Furthermore, combination vaccination resulted protection which was...
Abstract HER2 is a validated oncogenic target which overexpressed in many cancers. Although the approved HER2-specific biologics have improved standard of care HER2-positive breast and gastric cancers, significant unmet medical need exists due to intrinsic or acquired resistance. By randomizing two loops CH3 domain an IgG1 Fc fragment, we generated Fcab™ (Fc fragment with antigen binding), called FS102, binds high affinity (2 nM), recognizes epitope that does not overlap epitopes trastuzumab...
ABSTRACT In situ vaccination (ISV) is a promising cancer immunotherapy strategy, consists in the intratumoral administration of immunostimulatory molecules (adjuvants). The rationale that tumor antigens are abundant at site and therefore to elicit an effective anti-tumor immune response all needed adjuvant, which can turn immunosuppressive environment into immunologically active one. Bacterial Outer Membrane Vesicles (OMVs) potent adjuvants since they contain number microbe-associated...